



RECEIVED

1645

JUN 07 2001

~~HS~~

TECH CENTER 1600/2900

PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

In Re Application of: Françoise LECLERCQ et al.

Serial No.: 09/783,981

Group Art Unit: UNASSIGNED

Filed: February 16, 2001

Examiner: 1645

For: PROCESS FOR PREPARING FUNCTIONALIZED POLYALKYLENEIMINES,
COMPOSITIONS CONTAINING THEM AND USES THEREOF

1. Information Disclosure Statement and PTO-1449 form with 6 cited references

Dated: June 4, 2001

Docket No.: 03806.0500-00000

(Due Date: N/A)

WLS/cob - Mail Drop 216

144025-1

RECEIVED

JUN 07 2001

TECH CENTER 1600/2900

PATENT

Customer No. 22,852

Attorney Docket No. 03806.0500



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Françoise LECLERCQ et al.) Group Art Unit: 1645
Application No.: 09/783,981) Examiner: 1645
Filed: February 16, 2001)
For: PROCESS FOR PREPARING)
FUNCTIONALIZED)
POLYALKYLENEIMINES,)
COMPOSITIONS CONTAINING)
THEM AND USES THEREOF)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000

The following is a concise statement of relevance of the non-English language documents.

1. DE 19726186 A discloses complexes consisting of nucleic acid and polyethyleneimine (PEI) in which the PEI is covalently linked to hydrophilic polymers, such as polyethylene glycol, and methods for producing such complexes. A cellular ligand such as transferin may be bound to the PEI. The complexes disclosed may be used for producing pharmaceutical compositions for the transfer of therapeutically active genes into mammalian cells.

2. EP 0905254 A2 discloses the preparation and use of PEI having a molecular weight less than 50,000 Daltons and of vectors that contain such PEI for transferring nucleic acids into cells. A cell-specific ligand may be coupled to the PEI

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 4, 2001

By: 
William L. Strauss
Reg. No. 47,114

144021-1

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000